Comment on a Risk Stratification Tool for Relapse After Intravenous-to-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases
PMID: 40464796
Source: Am J Gastroenterol
Publication date:
2025-07-24
Year:
2025
Abstract
NULL